Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease
- 6 October 2016
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 180 (1) , 150-153
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Diverse and Targetable Kinase Alterations Drive Histiocytic NeoplasmsCancer Discovery, 2016
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsNew England Journal of Medicine, 2015
- Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester DiseaseJournal of Clinical Oncology, 2015
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaNew England Journal of Medicine, 2014
- Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesisBlood, 2014
- Recurrent RAS and PIK3CA mutations in Erdheim-Chester diseaseBlood, 2014
- Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b studyThe Lancet Oncology, 2014
- Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseBlood, 2014
- Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutationBlood, 2013
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012